Pacific Biosciences of California, Inc.
DB:P09 Rapporto sulle azioni
Pacific Biosciences of California Salute del bilancio
Salute finanziaria criteri di controllo 2/6 Pacific Biosciences of California ha un patrimonio netto totale di $453.1M e un debito totale di $893.1M, che porta il suo rapporto debito/patrimonio netto a 197.1%. Le sue attività totali e le sue passività totali sono rispettivamente $1.5B e $996.9M.
Informazioni chiave
197.1%
Rapporto debito/patrimonio netto
Indice di copertura degli interessi n/a Contanti US$471.15m Patrimonio netto US$453.12m Totale passività US$996.93m Totale attività US$1.45b
Aggiornamenti recenti sulla salute finanziaria
Mostra tutti gli aggiornamenti
New minor risk - Shareholder dilution Nov 14
Third quarter 2024 earnings released: US$0.22 loss per share (vs US$0.26 loss in 3Q 2023) Nov 09
PacBio Unveils the Vega System Nov 07
PacBio Announces SPRQ Chemistry for Revio Sequencing Systems Oct 29
Pacific Biosciences of California, Inc. to Report Q3, 2024 Results on Nov 07, 2024 Oct 11
President recently sold €155k worth of stock Sep 19
Chief Operating Officer recently sold €57k worth of stock Aug 22 Pacific Biosciences of California, Inc. Reports Goodwill Impairment for the Second Quarter Ended June 30, 2024 Aug 08
Pacific Biosciences of California, Inc. to Report Q2, 2024 Results on Aug 07, 2024 Jul 16
Pacific Biosciences of California, Inc.(NasdaqGS:PACB) dropped from Russell 2500 Growth Index Jul 03
First quarter 2024 earnings released: US$0.29 loss per share (vs US$0.36 loss in 1Q 2023) May 11
Pacific Biosciences of California, Inc., Annual General Meeting, Jun 18, 2024 May 01
Pacific Biosciences of California, Inc. Provides Revenue Guidance for the Second Quarter and Full Year 2024 Apr 16
PacBio Announces PureTarget Repeat Expansion Panel, Expanding Its Portfolio of End-To-End Clinical Research Solutions Mar 12
Insider recently bought €162k worth of stock Mar 07
Full year 2023 earnings released: US$1.21 loss per share (vs US$1.40 loss in FY 2022) Mar 04
President recently sold €445k worth of stock Feb 25
Full year 2023 earnings released: US$1.21 loss per share (vs US$1.40 loss in FY 2022) Feb 16
Pacific Biosciences of California, Inc Announces HiFi Prep Kit 96 and HiFi Plex Prep Kit 96 for Long-Read Sequencing Applications at Scale Feb 05
Pacific Biosciences of California, Inc. to Report Q4, 2023 Results on Feb 15, 2024 Jan 26
PacBio Announces New Nanobind Pandna Kit Enabling Hifi Optimized Dna Extraction Solutions Jan 15
Chief Operating Officer recently sold €221k worth of stock Jan 12
Pacific Biosciences of California, Inc. Announces Resignation of David Botstein from the Board Dec 12
PacBio Announces HiFi Solves, a Global Consortium of Clinical Genomics Research Leaders Nov 04
Third quarter 2023 earnings released: US$0.26 loss per share (vs US$0.34 loss in 3Q 2022) Nov 01
Pacific Biosciences of California, Inc. Appoints David Meline to Audit Committee Oct 28
Pacific Biosciences of California, Inc. Appoints David Meline to its Board of Directors Oct 17
Pacific Biosciences of California, Inc. to Report Q3, 2023 Results on Oct 30, 2023 Oct 13
Pacbio Announces Complete Computational Workflow for Human Whole Genome Sequencing Data Analysis Oct 12
President recently sold €918k worth of stock Sep 21
Chief Operating Officer recently sold €263k worth of stock Aug 20
Pacific Biosciences of California, Inc. (NasdaqGS:PACB) entered into an agreement to acquire Apton Biosystems, Inc. for approximately $110 million. Aug 04
Second quarter 2023 earnings released: US$0.28 loss per share (vs US$0.32 loss in 2Q 2022) Aug 03 Pacific Biosciences of California, Inc. (NasdaqGS:PACB) entered into an agreement to acquire Apton Biosystems, Inc. for $110 million.
Pacific Biosciences of California, Inc. to Report Q2, 2023 Results on Aug 02, 2023 Jul 22
Now 25% undervalued Jun 16 Pacific Biosciences of California, Inc. Announces Board Changes
VP & Chief Accounting Officer recently sold €60k worth of stock May 23
Insufficient new directors May 09
Full year 2022 earnings released: US$1.40 loss per share (vs US$0.89 loss in FY 2021) Feb 19
PacBio to Expand MAS-Seq Technology to 16S rRNA and Bulk RNA-Seq Solutions Feb 08
Pacific Biosciences of California, Inc. to Report Q4, 2022 Results on Feb 16, 2023 Feb 03
Insufficient new directors Jan 26 Pacific Biosciences of California, Inc. has completed a Follow-on Equity Offering in the amount of $175 million. Jan 26
Pacific Biosciences of California, Inc. has completed a Follow-on Equity Offering in the amount of $175 million. Jan 25
Pacific Biosciences of California, Inc. Provides Revenue Guidance for Fourth Quarter and Full Year 2022
Pacific Biosciences of California, Inc. Announces Board Appointments Nov 03
Pacific Biosciences of California, Inc. Withdraws its Financial Guidance Oct 27 Pacific Biosciences of California, Inc. to Report Q3, 2022 Results on Nov 07, 2022
PacBio Launches Single-Cell Transcriptome Solution Ushering in a New Era of RNA Discovery Oct 21
PacBio and Twist Bioscience Deliver Initial Portfolio of Target Enrichment Panels for HiFi Sequencing Oct 20
Chief Financial Officer recently sold €75k worth of stock Oct 04
PacBio Unveils A New Method for Comprehensive, Genome-Wide Tandem Repeat Analysis Sep 28
Second quarter 2022 earnings released: US$0.32 loss per share (vs US$0.21 loss in 2Q 2021) Aug 04
Pacific Biosciences of California, Inc. Provides Revenue Guidance for the Full Year 2022 Aug 04
Pacific Biosciences of California, Inc. Appoints Jeff Eidel as Chief Commercial Officer, Effective August 16, 2022 Jul 22
Pacific Biosciences of California, Inc. to Report Q2, 2022 Results on Aug 03, 2022 Jul 19
Pacific Biosciences of California, Inc. Announces Management Changes May 19
First quarter 2022 earnings released: US$0.37 loss per share (vs US$0.45 loss in 1Q 2021) May 06
Insufficient new directors Apr 27
Pacific Biosciences of California, Inc. to Report Q1, 2022 Results on May 04, 2022 Apr 21
Pacific Biosciences of California, Inc., Annual General Meeting, May 25, 2022 Apr 15
Insufficient new directors Apr 05
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Feb 16
Pacific Biosciences of California, Inc. to Report Q4, 2021 Results on Feb 15, 2022 Feb 02
Chief Operating Officer recently sold €519k worth of stock Jan 14
Pacific Biosciences of California, Inc. Provides Revenue Guidance for the Fourth Quarter and the Fiscal Year Ended December 31, 2021 Jan 12
PacBio’s New HiFiViral Surveillance Kit Performance is Not Impacted by Omicron Mutations, Delivering Complete SARS-CoV-2 Genomes for All Circulating Variants Dec 29
Insufficient new directors Dec 06
Third quarter 2021 earnings released: EPS US$0.082 (vs US$0.14 loss in 3Q 2020) Nov 03 Pacific Biosciences of California, Inc. (NasdaqGS:PACB) completed the acquisition of Omniome, Inc.
Pacific Biosciences of California, Inc. (NasdaqGS:PACB) acquired Circulomics, Inc. Aug 05
Second quarter 2021 earnings released: US$0.21 loss per share (vs US$0.15 loss in 2Q 2020) Aug 04
Senior Fellow & Director Michael Hunkapiller has left the company Jun 18
VP & Chief Accounting Officer has left the company May 19
First quarter 2021 earnings released: US$0.45 loss per share (vs US$0.008 profit in 1Q 2020) May 01
Pacific Biosciences of California, Inc. Launches New HiFi Sequencing Workflow Apr 27
Revenue beats expectations Mar 02
Full year 2020 earnings released: EPS US$0.18 (vs US$0.55 loss in FY 2019) Mar 02
VP & Chief Accounting Officer recently sold €124k worth of stock Feb 27
Pacific Biosciences Sequel II Systems Deployed to Scale-Up Global Viral Surveillance Initiatives Focused on COVID-19 Feb 19
Independent Director recently sold €4.2m worth of stock Feb 19
Pacific Biosciences of California, Inc. announced that it has received $900 million in funding from SB Northstar LP Feb 18
Full year 2020 earnings released: EPS US$0.18 (vs US$0.55 loss in FY 2019) Feb 12
Revenue beats expectations Feb 12
New 90-day high: €42.00 Feb 12
Pacific Biosciences of California, Inc. announced that it expects to receive $900 million in funding from SB Northstar LP Feb 11
Pacific Biosciences of California, Inc., Annual General Meeting, Jun 16, 2021 Feb 10
Analisi della posizione finanziaria
Passività a breve termine: Le attività a breve termine ( $584.2M ) di P09 superano le sue passività a breve termine ( $60.0M ).
Passività a lungo termine: Le attività a breve termine di P09 ( $584.2M ) non coprono le sue passività a lungo termine ( $936.9M ).
Storia e analisi del rapporto debito/patrimonio netto
Livello di debito: Il rapporto debito netto/patrimonio netto ( 93.1% ) di P09 è considerato alto .
Riduzione del debito: Il rapporto debito/patrimonio netto di P09 è aumentato da 30.5% a 197.1% negli ultimi 5 anni.
Analisi della pista di contanti Per le società che in passato sono state mediamente in perdita, valutiamo se hanno almeno un anno di liquidità.
Pista di liquidità stabile: P09 ha una pista di cassa sufficiente per più di un anno in base al suo attuale flusso di cassa libero .
Previsione Cash Runway: Dati insufficienti per determinare se P09 ha una sufficiente pista di cassa se il suo flusso di cassa libero continua a crescere o a ridursi in base ai tassi storici.
Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"control","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}